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Summary
Recent evidence suggests that lipopolysaccharide (LPS) endotoxaemia in a rat
causes significant mucosal injury. Our objective was to determine the effects
of glutamine (Gln) on Toll-like receptor 4 (TLR-4), myeloid differentiation
factor 88 (Myd88) and tumour necrosis factor (TNF)-a receptor-associated
factor 6 (TRAF6) expression in intestinal mucosa following LPS endotox-
aemia in a rat. For this purpose, male Sprague–Dawley rats were assigned
randomly to one of three experimental groups of 10 rats each: (i) control rats
underwent intraperitoneal (i.p.) injection of sterile saline once a day; (ii) rats
were treated with LPS given i.p. once a day at a dose of 10 mg/kg for 48 h (two
doses); and (iii) rats were pretreated with oral Gln given in drinking water
(2%) 48 h before and following injection of LPS. Intestinal mucosal param-
eters, enterocyte proliferation and apoptosis were determined at death. TLR-4
and MyD88 mRNA expression was measured with reverse transcription–
polymerase chain reaction (RT–PCR). TLR-4 and MyD88 protein expression
were analysed by Western immunoblotting. We observed a statistically signifi-
cant (P < 0·05) decrease in mucosal weight, mucosal DNA and enterocyte
proliferation and a significant increase in enterocyte apoptosis in rat intestine,
following LPS administration. These changes were attenuated significantly by
dietary Gln. Expression of TLR-4, MyD88 and TRAF6 mRNA in the mucosal
ileum was significantly higher in LPS rats versus control rats (P = 0·0006,
P = 0·0015, P = 0·03, respectively) as well as TLR-4 and MyD88 protein
expression. The administration of Gln reduced significantly the expression
of TLR-4, MyD88 and TRAF6 (P = 0·023, P = 0·014, P = 0·035, respectively)
mRNA as well as TLR-4 and MyD88 protein expression in ileum compared to
LPS animals. We did not find a significant change in the expression of TLR-4,
MyD88 or TRAF6 in the jejunum of different groups. We conclude that treat-
ment with Gln was associated with down-regulation of TLR-4, MyD88 and
TRAF6 expression and concomitant decrease in intestinal mucosal injury
caused by LPS endotoxaemia in a rat.
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Toll-like receptors (TLRs) are an ancient conserved receptor
family that regulate anti-microbial host defence in plants,
invertebrates and mammals [1]. Individual TLRs recognize
distinct pathogen-associated molecular patterns (PAMPs)
that have been conserved evolutionarily in specific classes of
microbes. Interaction of PAMPs with TLRs triggers a
complex signalling pathway that leads to the activation of
the immune system. There are more than 10 identified
members of the TLR family, with well-defined specificities
to various components of bacteria, viruses or fungi [2]. The
best-characterized member of this family is Toll-like recep-
tor 4 (TLR-4), the receptor for lipopolysaccharide (LPS),
which is the best-known and first-discovered bacterial cell
wall component that can elicit cellular responses. TLR-4 is
responsible for the recognition of bacterial endotoxin or
LPS and for initiation of Gram-negative bacillary septic
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shock syndrome [3,4]. Interaction between LPS and TLR-4
leads to the formation of an LPS signalling complex con-
sisting of surface molecules, such as CD14 and MD2, as well
as intracellular adaptor molecules, including myeloid differ-
entiation primary response gene 88 (MyD88) and tumour
necrosis factor (TNF)-a receptor association factor 6
(TRAF6), and activation of transcription factors such as
nuclear factor kB (NFkB), which then induce activation of
the inflammatory genes, such as TNF-a, interleukin (IL)-1,
IL-6 and IL-8 [5].
Extensive studies in various experimental models have
established that intestinal mucosal injury impairs gut
barrier function and leads to bacterial translocation of bac-
teria and endotoxin across the intestinal mucosa, which
could result in the systemic inflammatory response syn-
drome and multiple organ failure [6]. However, in a recent
study we have demonstrated that LPS endotoxaemia itself
impairs the integrity of the gastrointestinal mucosa [7].
This mechanism may be responsible for bacterial transloca-
tion and development of the systemic inflammatory
response in septic patients. Therefore, understanding of the
mechanisms by which LPS impairs intestinal integrity (e.g.
the TLR-4 pathway) as well as identification of those factors
that prevent intestinal mucosal injury might suggest new
therapeutic strategies in maintaining gut barrier function
and in improving the outcome in patients suffering from
endotoxaemia and sepsis.
Glutamine (Gln) is a non-essential amino acid which is
also considered an essential nutrient during major injury or
severe illness. It has been demonstrated that a rapid deple-
tion of Gln stores occurs during critical illness [8–10]. Gln
has been shown to be beneficial in the prevention of infec-
tious morbidity and mortality in seriously ill patients, due in
part to its ability to maintain the integrity of intestinal
mucosal epithelium [11–14].
Several possible mechanisms have been described to
explain the positive effects of Gln on intestine. These
include replication of enterocytes, maintenance of gut-
associated lymphoid tissue function and cellularity. It has
also been suggested that Gln influences replication of
immune cells, T helper function and responsiveness and
synthesis of immunoglobulin A (IgA) [15]. Recently,
Uehara et al. demonstrated that Gln pretreatment improves
intestinal tissue injury significantly in a rat model of
LPS endotoxaemia. Gln exerts a protective effect by its
site-specific induction of haem oxygenase-1 in the mucosal
cells in the ileum and the colon and attenuates tissue
inflammation, apoptotic cell death and decreases
mortality in rats [16]. We have shown recently that oral
Gln prevents gut mucosal injury and improves mucosal
recovery following lipopolysaccharide endotoxaemia in a
rat [17].
In this study, we examined the effect of Gln administra-
tion on TLR-4, MyD88 and TRAF6 mRNA expression in
small intestine following LPS endotoxaemia in a rat.
Materials and methods
Animals
The experiment and animal care were conducted in compli-
ance with the guidelines established by the Guide for the
Care and Use of Laboratory Animals, Rappaport Faculty of
Medicine, Technion (Haifa, Israel).
Male Sprague–Dawley rats weighing 250–280 g were uti-
lized for this study. Animals were housed in individual wire-
bottomed Plexiglas cages kept at 21°C on 12-h day–night
cycles for at least 4 days with free access to water and were
pair-fed with a standard chow.
Experimental design
Animals were assigned randomly to one of three experimen-
tal groups of 10 rats each: (1) control rats (group A) under-
went intraperitoneal (i.p.) injection of sterile saline once a
day; (2) LPS rats (group B) rats were treated with LPS given
i.p. once a day at a dose of 10 mg/kg for 48 h (two doses); and
(3) LPS–Gln (group C) rats were pretreated with oral Gln
given in drinking water (2%) 48 h before and following
injection of LPS. Twenty-four h following the last LPS injec-
tion, animals were anaesthetized with i.p. sodium pentobar-
bital (45 mg/kg) and were killed by open pneumothorax.
Intestinal mucosal parameters
The small bowel was excised quickly, washed with cold
isotonic saline and divided into two segments: proximal
jejunum and terminal ileum. Each segment was weighed
and cut longitudinally. Mucosa was scraped using a
microspatula, collected and weighed. DNA was extracted
from the mucosa of jejunum and ileum using TRIzol
reagent, as described by Chomczynski [18]. Quantitization
of DNA was performed by spectrophotometry using A260
value (one A260 unit equals 50 mg of double-stranded DNA)
and calculated as mg/cm bowel length/100 g body weight.
Crypt cell proliferation and villus cell apoptosis
Standard 5-bromodeoxyuridine (5-BrdU) labelling reagent
(Zymed Laboratories, Inc., San Francisco, CA, USA) was
injected i.p. at a dose of 1 ml/100 g body weight 2 h before
sacrifice. Crypt cell proliferation was assessed using biotiny-
lated monoclonal anti-BrdU antibody system provided in kit
form (Zymed Laboratories, Inc.). An index of proliferation
was determined as the ratio of crypt cells staining positively
for BrdU per 10 crypts.
Immunohistochemistry for caspase-3 (caspase-3 cleaved
concentrated polyclonal antibody; dilution 1 : 100; Biocare
Medical, Walnut Greek, CA, USA) was performed for
identification of apoptotic cells using a combination of
the streptovidin–biotin–peroxidase method and microwave
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antigen retrieval on formalin-fixed, paraffin-embedded
tissues according to the manufacturer’s protocols. The apo-
ptotic index (AI) was defined as the number of apoptotic
caspase-3-positive cells per 10 villi.
All measurements were performed by a qualified patholo-
gist blinded as to the source of intestinal tissue.
TLR-4, MyD88 and TRAF6 mRNA expression by
semiquantitative reverse transcription–polymerase
chain reaction (RT–PCR) analysis
Total RNA from ileal and jejunal rat epithelial cells was iso-
lated with MasterPure™ (Epicentre, Madison, WI, USA).
cDNA was generated from 1 mg of total RNA using reverse
transcriptase (Reverse-iT™ ABgene, Surrey, UK) and random
decamers (ABgene). RT products were subjected to poly-
merase chain reaction (PCR) amplification with GoTaq®
Green Master Mix (Promega, Madison, WI, USA). The
annealing temperature was 54°C. All primers were purchased
from Genosys, Sigma, Rehovot, Israel. The cDNA products
were separated on 2% agarose gel containing ethidium
bromide. The bands were visualized and photographed using
ultraviolet (UV) transilluminator and analysed by Tina soft-
ware.b-actin cDNA product was used as a standard to equiva-
lent levels of total RNA subjected to RT–PCR and used to
normalize the band intensity of TLR-4 MyD88 and TRAF6.
Western blot analysis
For separation of total protein, frozen specimens were
homogenized in 50 mM Tris buffer pH 7·4 containing
150 mM NaCl, 5 mM ethylenediamine tetraacetic acid
(EDTA), 0·5% NP40 and TM protease inhibitor cocktail.
Following centrifugation (16 000 g, 10 min), the supernatant
(100 mg total protein, according to calibration) was diluted
1 : 1 in electrophoresis sample buffer containing 20% (v/v)
glycerol, 4% (w/v) sodium dodecyl sulphate (SDS), 250 mM
Tris–HCl, pH 6·8, 10% (v/v) 2-mercaptoethanol and
0·5 mg/ml bromophenol blue. The protein sample was sepa-
rated on 10% SDS acrylamide gel and transferred to a nitro-
cellulose membrane. Quality of transfer was assayed by
Ponceau staining. Following blocking [Tween–Tris-buffered
saline (TBS) containing 2% bovine serum albumin (BSA)]
of non-specific binding sites, membranes were incubated at
4°C overnight with primary antibody. After washing, blots
were incubated for 1 h at room temperature with secondary
antibody in Tween–TBS (in 0·5% Tween). Data regarding
specific antibody used, molecular weight, dilution, and sec-
ondary antibody are summarized in Table 1. The blots were
then developed with Amersham’s enhanced chemilumines-
cence (ECL) reagent and exposed to XLS Kodak film for
20–30 s. Protein levels were analysed three times for each
sample. A single batch of protein of rat intestine in three
different concentrations was used as a positive control and
for normalization. Protein concentration was measured
using Bradford reagent (Bio-Rad Laboratories Ltd., Rishon
Le Zion, Israel). The results are expressed as the ratio of
target protein over b-actin protein expression.
Statistical analysis
The data was analysed by one-way analysis of vari-
ance (anova) following unpaired Student’s t-test with
Bonferroni’s multiple comparison tests. Differences at
P = 0·05 were considered statistically significant.
Results
Intestinal mucosal parameters
LPS rats (group B) had a significant decrease in bowel weight
in jejunum (15%, P < 0·05), mucosal weight in jejunum
(33%, P < 0·05) and ileum (43%, P < 0·05), mucosal DNA in
jejunum (54%, P < 0·05) and ileum (53%, P < 0·05) com-
pared to control animals (group A) (Table 2). Following oral
Gln administration, LPS–Gln rats (group C) demonstrated a
significant increase in jejunal (18%, P < 0·05) and ileal (18%,
P < 0·05) bowel weight, ileal mucosal weight (44%, P < 0·05)
and a twofold increase in jejunal (P < 0·05) and ileal
(P < 0·05) mucosal DNA content compared to LPS-
untreated animals (group B).
Enterocyte proliferation and apoptosis
Enterocyte proliferation decreased significantly in LPS rats
(group B) in both jejunum (18%, P < 0·05) and ileum (22%,
P < 0·05) compared to control animals (group B) (Table 2).
Pretreatment with oral Gln (group C) led to a significant
increase in the enterocyte proliferation rate in jejunum
(21%, P < 0·05) and ileum (14%, P < 0·05) compared to LPS
animals (group B). The number of apoptotic cells increased
significantly in LPS rats (group B) in jejunum (2·5-fold,
P < 0·05) and ileum (2·5-fold, P < 0·05) compared to control
animals (Table 1). LPS–Gln rats (group C) showed a trend
Table 1. Data for first and second antibodies used for Western blot analysis.
Second antibody (dilution) Size (kDa) Manufacturer and catalogue number Antibody (dilution)
Mouse monoclonal (1:7500) 43 Sigma Aldrich b-actin (1:2000)
Goat polyclonal (1:7500) 33 Santa Cruz sc-8196 MyD88 (N-19) (1:300)
Mouse IgG2b (1:3000) 88 Imgenex (Almog) IMG-5031A TLR-4 (1:200)
MyD88: myeloid differentiation factor 88; TLR-4: Toll-like receptor 4.
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towards a decrease in the enterocyte apoptosis in jejunum
and ileum compared to LPS rats (group B); however, this
trend did not achieve statistical significance (Fig. 1).
TLR-4, MyD88 and TRAF6 mRNA expression
LPS rats (group B) showed a significant increase in TLR-4
mRNA expression versus controls (P = 0·0006) in ileum and
trend towards an increase in TLR-4 mRNA expression in
jejunum; however, this trend was not statistically significant
(Fig. 2). Treatment with Gln (group C) resulted in a signifi-
cant decrease in ileal TLR-4 mRNA expression (versus LPS
rats, group B) (P = 0·023) and a trend towards a decrease in
jejunum TLR-4 mRNA expression; however, this trend did
not achieve statistical significance. Changes in MyD88
mRNA expression were similar to those of TLR-4 mRNA
expression (Fig. 3). LPS endotoxaemia (group B) resulted in
a significant increase in MyD88 mRNA expression in ileum
compared to control rats (group A) (P = 0·0015). LPS–Gln
rats (group C) showed a significant decrease (versus LPS
rats) in MyD88 mRNA expression in ileum (P = 0·014) and a
Table 2. Effect of lipopolysaccharide (LPS) endotoxaemia and treat-
ment with glutamine on intestinal mucosal parameters.
Parameters Control LPS LPS–Gln
Bowel weight (mg/cm/100 g)
Jejunum 20  0·3 17  1* 20  0·6†
Ileum 18  1 17  1 20  0·7*†
Mucosal weight (mg/cm/100 g)
Jejunum 9  0·5 6  0·5* 7  0·4*
Ileum 8  0·6 4·6  0·3* 6·6  0·4*†
Mucosal DNA (mg/cm/100 g)
Jejunum 12·3  0·2 5·7  1·2* 11·7  0·4†
Ileum 11·7  1·1 5·5  1·4* 10·5  0·4†
Cell proliferation (BrdU-positive cells/10 crypts)
Jejunum 142  10 116  2* 140  3†
Ileum 156  14 121  6* 138  4†
Cell proliferation (apoptotic cells/10 villi)
Jejunum 1·3  0·2 3·2  0·7* 2·7  0·5*
Ileum 1·3  0·5 3·0  0·6* 2·3  0·1
*P < 0·05 LPS versus control; †P < 0·05 LPS–Gln versus LPS. LPS: rats
treated with LPS; LPS–Gln: rats treated with LPS and glutamine; BrdU:
bromodeoxyuridine.
Fig. 1. Effect of lipopolysaccharide (LPS)
endotoxaemia and oral glutamine on crypt cell
proliferation and enterocyte apoptosis;
5-bromodeoxyuridine (5-BrdU) incorporation
into proliferating jejunal and ileal crypt cells
was detected with a goat anti-BrdU antibody.
The representative sections (on the left side)
demonstrate that cell proliferation decreased
following LPS compared to sham animals.
Following administration of oral glutamine,
LPS rats demonstrated a significant increase in
a number of proliferating cells compared to
LPS non-treated animals.
Immunohistochemistry for caspase-3 was used
to determine enterocyte apoptosis. The
representative sections (on the right side)
demonstrate that the number of apoptotic cells
increased significantly following LPS compared
to control animals and decreased significantly
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trend towards a decrease in the jejunum; however, this trend
was not statistically significant. LPS rats (group B) showed a
significant increase in TRAF6 mRNA expression versus con-
trols (P = 0·03) in ileum and not in the jejunum (Fig. 4).
Treatment with Gln (group C) resulted in a significant
decrease in ileal TRAF6 mRNA expression (versus LPS rats,
group B) (P = 0·035).
Interestingly, the TLR-4, MyD88 and TRAF6 mRNA
expression in the control groups was significantly higher in
the ileum compared to the jejunum (P = 0·05, P = 0·00019
and P = 0·016, respectively).
Expression of TLR-4 and MyD88 proteins
Western blot analysis confirmed the changes in TLR-4 and
MyD88 (Fig. 5). In sham segments, the expression of TLR-4
and MyD88 proteins was consistently higher in jejunal com-
pared to ileal segments (P < 0·05). A significant increase in
expression of TLR-4 and MyD88 was found in ileum of LPS
rats compared to sham animals (P < 0·05). Treatment with
Gln resulted in a significant decrease in TLR-4 (P < 0·05) and
MyD88 (P < 0·05) protein expression in ileum compared to
LPS non-treated animals (group B).
Discussion
The intestinal epithelium serves as an important defence
against luminal bacteria [19,20]. One of the mechanisms by
which the intestinal epithelium controls the microflora and
responds more actively to encroaching pathogens is referred
to as the innate intestinal epithelial defence and is the TLR
system. TLR-4 mRNA is present in mouse and human intes-
tinal epithelial cells TLR-4 lines [21]. TLR-4 is also expressed
on macrophages, dendritic cells, airway epithelia, endothelial
cells and smooth muscle [22,23].
Involvement of TLR-4 in LPS responses was first suggested
by the discovery that TLR-4 from spontaneous LPS-
hyporesponsive mutant mice, C3H/HeJ, has a point muta-
tion that causes an inability to activate NFkB [24–26].
Subsequently, using generated TLR-4-deficient mice, TLR-4































Fig. 2. Toll-like receptor-4 (TLR-4) mRNA expression levels in the
intestinal mucosa. Following lipopolysaccharide (LPS) administration,
the expression of TLR-4 mRNA expression increased significantly
compared to the control group in the ileal mucosa (P = 0·0006).
Pretreatment with oral glutamine (LPS–Gln) decreased the elevation
of TLR-4 mRNA expression significantly compared to the LPS group
in the ileal mucosa (P = 0·023). Similar results without statistical
significance were found in the jejunal mucosa. Data shown are

































Fig. 3. Myeloid differentiation factor 88 (MyD88) mRNA expression
levels in the intestinal mucosa. Following lipopolysaccharide (LPS)
administration, the expression of MyD88 mRNA expression increased
significantly compared to the control group in the ileal mucosa
(P = 0·0015). Pretreatment with oral glutamine (LPS–Gln) decreased
the elevation of MyD88 mRNA expression significantly compared to
the LPS group in the ileal mucosa (P = 0·014). Similar observations
without statistical significance were found in the jejunal mucosa. Data


































Fig. 4. Tumour necrosis factor (TNF)-a receptor-associated factor 6
(TRAF6) mRNA expression levels in the intestinal mucosa. Following
lipopolysaccharide (LPS) administration, the expression of TRAF6
mRNA expression increased significantly compared to the control
group in the ileal mucosa (P = 0·03). Pretreatment with oral
glutamine (LPS–Gln) decreased the elevation of TRAF6 mRNA
expression significantly compared to the LPS group in the ileal
mucosa (P = 0·035). We did not find similar results in the jejunal
mucosa. Data shown are mean  standard error of the mean.
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responses [26]. While TLR-4 recognition of LPS is required
for clearance of Gram-negative organisms, it is believed that
the degree and the duration of this proinflammatory cytok-
ine secretion can become harmful to the host [27–29]. The
LPS receptor complex consists of two interacting receptors
(CD14 and TLR-4) and an associated protein (MD-2). When
engaged by LPS, as in Gram-negative infection, this complex
transduces a signal detected by MyD88, which is passed
onwards by a cascade of the receptor-associated kinase
(IRAKs), receptor-associated factor 6 (TRAF6) and NFkB-
inducing kinase (NIK), resulting in activation of NFkB. In a
recent experiment, we have shown that LPS endotoxaemia
causes a significant mucosal hypoplasia in a rat which
resulted in decreased enterocyte proliferation and increased
apoptosis [7,8]. In this study we present a similar observa-
tion that demonstrates decreased mucosal weight, decreased
mucosal DNA, decreased enterocyte proliferation and
increased enterocyte apoptosis in rat intestine following LPS
administration.
Analysis of gene and protein expression of selected
members of the TLR-5 pathway revealed that their expres-
sion profiles vary greatly along the proximal–distal axis of
the gut. We found that administration of LPS was associated
with up-regulation of TLR-4, Myd88 and TRAF6 mRNA
expression in the ileal mucosa; however, in jejunum these
changes were not statistically significant. In accordance with
mRNA expression, TLR-4 and Myd88 protein expression
were found to be up-regulated in ileum of LPS rats com-
pared to control animals. The up-regulation expression of
TLR-4 and Myd88, which leads to induction of inflamma-
tory cytokines such as TNF-a, IL-1 and IL-6, can explain the
developed widespread intestinal mucosal injury. Similar
findings were reported in a study conducted by William et al.
[30]. The authors found a correlation between induction of
sepsis by caecal ligation and puncture, early expression of
TLR-4 and onset of animal death.
The present study demonstrates that enteral Gln improves
intestinal recovery following LPS administration. This is
evident from increased bowel and mucosal weight, mucosal
DNA and index of proliferation, although cell apoptosis did
not change significantly with dietary Gln supplementation.
This positive effect of Gln on intestinal mucosa was accom-
panied by a decrease in the expression of TLR-4, Myd88 and
TRAF6 mRNA in the mucosal intestine. Specifically, the
decrease of TLR-4, Myd88 and TRAF6 mRNA expression as
well as TLR-4 and Myd88 protein expression in LPS–Gln
versus LPS was statistically significant in the ileum. In fact, we
found that the expression of TLR-4, MyD88 and TRAF6 in
the control group (group A) was higher in the ileum com-
pared to the jejunum. This observation might explain the
different response of the TLR-4, Myd88 and TRAF6 mRNA
expression in the ileal compare to the jeunal mucosa follow-
ing LPS administration. Interestingly, Uehara et al. also
found that Gln exerts a higher expression of haem oxygenase
1 in the ileum than in the jejunum [17].
Expression of TLR-4, MyD88 and TRAF6 mRNA
decreased after Gln administration, which coincided with a
decrease in TLR-4 and MyD88 protein expression. This
finding is consistent with the Abreu et al. study [28]. They
suggested that this down-regulation may be a mechanism by
which intestinal epithelial cells protect against dysregulated
immune signalling in response to Gram-negative commen-
sal bacteria and their products. In a recent study, Cario and
Podolsky demonstrated that in patients with inflammatory
bowel disease the TLR-4 expression was higher than in
healthy controls. They concluded that aberrant TLR-4
expression may play an important role in the loss of toler-
ance to the enteric bacteria [21].
In summary, LPS endotoxaemia causes intestinal mucosal
injury and increases TLR-4 MyD88 and TRAF6 mRNA
expression. Gln improves intestinal recovery and decreases
TLR-4, MyD88 and TRAF6 mRNA expression. We conclude,
therefore, that TLR-4, MyD88 and TRAF6 expression may be
responsible for the harmful effect of LPS and positive effect
of Gln on intestinal recovery. The positive effect of Gln on
intestinal structure after LPS endotoxaemia may be consid-
ered as a mechanism via which immunonutrition helps in































Fig. 5. Protein expression of Toll-like receptor-4 (TLR-4) and myeloid
differentiation factor 88 (MyD88) in lipopolysaccharide (LPS) rats
compared to control animals. b-actin was used to normalize loading.
LPS rats demonstrate a significant increase in TLR-4 and MyD88
expression in ileum compared to control animals. Protein expression
of TLR-4 and MyD88 decreased significantly in ileum following
glutamine administration. Data shown are mean  standard error of
the mean. *P < 0·05 versus control; †LPS–Gln versus LPS.
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